Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved
The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer ( nmCRPC ) who are at high risk of developing metastatic disease.
The EC approval is based on data from the pivotal phase 3 SPARTAN study, which was published in The New England Journal of Medicine.
The study has assessed the efficacy and safety of Apalutamide plus androgen deprivation therapy ( ADT ) versus placebo plus ADT in patients with nmCRPC who had a rapidly rising prostate specific antigen ( PSA ) level despite receiving continuous ADT.
Findings from the study showed that Apalutamide plus ADT, has significantly reduced the risk of developing distant metastasis or death ( metastasis free survival [ MFS ] ) by 72%, compared to placebo in combination with ADT ( hazard ratio, HR = 0.28; 95% CI, 0.23-0.35; P less than 0.001 ).
The median MFS was improved by over two years ( 40.5 months vs. 16.2 months ) in patients with nmCRPC whose PSA is rapidly rising.
One of the key goals in prostate cancer treatment is to delay the disease from spreading. Once the cancer spreads, it can become less responsive to treatment, impacting patients’ quality of life and ultimately worsening their prognosis.
Median survival for these patients is approximately three years.
The most common grade 3/4 treatment-emergent adverse events in the SPARTAN study were hypertension ( 14.3% vs. 11.8% ), rash ( 5.2% vs. 0.3% ), fall ( 1.7% vs. 0.8% ) and fracture ( 2.7% vs. 0.8% ).
Treatment discontinuation due to adverse events was 11% in the Apalutamide arm compared to 7% in the placebo arm.
Rates of serious adverse events were similar in the Apalutamide in combination with ADT arm versus placebo in combination with ADT arm ( 25% vs. 23%, respectively ).
Apalutamide is a next-generation oral androgen receptor ( AR ) inhibitor that blocks the androgen signaling pathway in prostate cancer cells.
Apalutamide inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the AR; by stopping the AR from entering the cancer cells; and by preventing the AR from binding to the DNA of the cancer cell.
Non-metastatic castration-resistant prostate cancer ( CRPC ) refers to a disease stage when the cancer no longer responds to medical or surgical treatments that lower testosterone, but has not yet been discovered in other parts of the body using a bone scan or CT scan.
Features include: lack of detectable metastatic disease; rapidly rising prostate-specific antigen while on androgen deprivation therapy and serum testosterone level below 50 ng/dL.
Ninety percent of patients with non-metastatic CRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.
The relative 5-year survival rate for patients with distant stage castration sensitive or castration resistant prostate cancer is 30%. ( Xagena )
Source: Janssen, 2019
Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...
Apalutamide vs placebo in patients with non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy: health-related quality of life at final analysis of the SPARTAN study
The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...
European Union: Lynparza approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer: final survival results from SPARTAN, a phase III trial
SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...
Darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer: overall survival results of phase III ARAMIS study
Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...
IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met its co-primary endpoint of radiographic progression free survival in patients with PTEN loss tumours
Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...
Apalutamide improves overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer
Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...
For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...